Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
| Autor: | Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., Mitsudomi, T. * |
|---|---|
| Zdroj: | In Annals of Oncology December 2019 30(12):1978-1984 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|